Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited (LINCOLN.NS) Stock Overview
Explore Lincoln Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
12.1B
P/E Ratio
13.79
EPS (TTM)
$43.84
ROE
0.13%
LINCOLN.NS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Lincoln Pharmaceuticals Limited (LINCOLN.NS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 54.57, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $770.50.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 13.79 and a market capitalization of 12.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.